The cardiac ryanodine receptor luminal Ca2+ sensor governs Ca2+ waves, ventricular tachyarrhythmias and cardiac hypertrophy in calsequestrin-null mice.

Jingqun Zhang,Biyi Chen,Xiaowei Zhong,Tao Mi,Ang Guo,Qiang Zhou,Zhen Tan,Guogen Wu,Alexander W Chen,Michael Fill,Long-Sheng Song,S R Wayne Chen
DOI: https://doi.org/10.1042/BJ20140126
IF: 3.766
2014-01-01
Biochemical Journal
Abstract:CASQ2 (cardiac calsequestrin) is commonly believed to serve as the SR (sarcoplasrnic reticulum) luminal Ca2+ sensor. Ablation of CASQ2 promotes SCWs (spontaneous Ca2+ waves) and CPVT (catecholaminergic polymorphic ventricular tachycardia) upon stress but not at rest. How SCWs and CPVT are triggered by stress in the absence of the CASQ2-based luminal Ca2+ sensor is an important unresolved question. In the present study, we assessed the role of the newly identified RyR2 (ryanodine receptor 2)-resident luminal Ca2+ sensor in determining SCW propensity, CPVT susceptibility and cardiac hypertrophy in Casq2-KO (knockout) mice. We crossbred Casq2-KO mice with RyR2 mutant (E4872Q(+/-)) mice, which lack RyR2-resident SR luminal Ca2+ sensing, to generate animals with both deficiencies. Casq2(+/-) and Casq2(-/-) mice showed stress-induced VTs (ventricular tachyarrhythmias), whereas Casq2(+/-) /E4872Q(+/-) and Casq2(-/-) /E4872Q(+/-) mice displayed little or no stress-induced VTs. Confocal Ca2+ imaging revealed that Casq2(-/-) hearts frequently exhibited SCWs after extracellular Ca2+ elevation or adrenergic stimulation, whereas Casq2(-/-) /E4872Q+/- hearts had few or no SCWs under the same conditions. Cardiac hypertrophy developed and CPVT susceptibility increased with age in Casq2(-/-) mice, but not in Casq2(-/-) /E4872Q+/- mice. However, the amplitudes and dynamics of voltage-induced Ca2+ transients in Casq2(-/-) and Casq2(-/-) /E4872Q(+/-) hearts were not significantly different. Our results indicate that SCWs, CPVT and hypertrophy in Casq2-null cardiac muscle are governed by the RyR2-resident luminal Ca2+ sensor. This implies that defects in CASQ2-based luminal Ce2+ sensing can be overridden by the RyR2-resident luminal Ca2+ sensor. This makes this RyR2-resident sensor a promising molecular target for the treatment of Ca2+-mediated arrhythmias.
What problem does this paper attempt to address?